Biocytogen Pharmaceuticals, a global biotech firm specialising in novel antibody therapeutics, has agreed to a licensing deal with Pheon Therapeutics, an antibody-drug conjugate (ADC) developer. Pheon Therapeutics is set to develop and commercialize an antibody created with Biocytogen Pharmaceuticals’ exclusive RenMice platforms, a technology that generates fully human antibodies with low immunogenicity, high diversity, species […]
German pharma company Boehringer Ingelheim has signed a deal worth €1.18 billion to acquire NBE-Therapeutics, a clinical-stage Switzerland-based biotech company, focused on developing antibody-drug conjugates (ADCs) and advancing targeted cancer therapies. Through the acquisition, Boehringer Ingelheim will gain access to the Swiss firm’s iADC platform, which is capable of creating immune stimulatory ADCs with an […]
